Patients baseline characteristics
| N | ||
|---|---|---|
| Age, years* | 1125 | 56.7 (22.1–88.8) |
| Female | 1125 | 89.5% |
| Current or former smoker | 1125 | 39.6% |
| BMI, kg/m2* | 1055 | 26.6 (15.8–56.2) |
| Disease duration, years* | 1124 | 12.7 (0.7–56.7) |
| Rheumatoid factor+ | 1105 | 78.7% |
| ACPA+ | 479 | 76.8% |
| Erosive disease | 1105 | 55.2% |
| Extra-articular manifestation ≥1 | 1118 | 23.3% |
| Drugs in use: | % | |
| – Glucocorticoids | 1125 | 47.0 |
| – NSAIDs | 1125 | 9.0 |
| – Synthetic DMARDs | 1125 | 90.8 |
| – Methotrexate | 1125 | 66.5 |
| – Biologic DMARDs | 1125 | 36.1 |
| Erythrocyte sedimentation rate (ESR), mm/1st hour* | 933 | 21 (1–140) |
| C-reactive protein, mg/dL* | 954 | 0.7 (0–76.1) |
| DAS28-ESR* | 932 | 3.5 (0.3–8.2) |
| HAQ-DI* | 1121 | 0.875 (0–3) |
*Results in median (range).